ArticlePloS one2025
Occult metastases and survival of lung cancer by clinical diagnosis and CT screening: A simulation study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesIt is significant to know how much early detection and screening could reduce the proportion of occult metastases and benefit NSCLC patients.
methodsWe used previously designed and validated mathematical models to obtain the characteristics of LC in the population including undetectable metastases at the time of diagnosis. The survival was simulated using the survival functions from Surveillance, Epidemiology and End Results (SEER) data stratified by stage.
resultsBased on the simulations, 35.3% of patients diagnosed with stage N0M0 and 56.9% of those diagnosed with stage N1M0 had nodal or distant metastases that were not discovered at the time of diagnosis. Among clinically detected Stage I lung cancers with tumor diameter 1-2 cm, 78% were true stage N0M0 (no occult metastases) while it was only 37% for patients with tumor diameters of 2-3 cm. This size threshold can be translated into a 0.75-year the "window of opportunity" for the curable disease. In a comparative analysis of two simulated groups of individuals: (1) clinically diagnosed (2) diagnosed by screening with a varying screening frequency (quarterly, biannual, annual and biennial), it was estimated that, once the screening intervals become shorter, substantially more cancers are found, but at an expense of a higher radiation exposure. The simulation projected that the mortality reduction in screened patients depending on the frequency, ranged from 15.04% to 18.82%.
conclusionsThe probability of occult metastases significantly increases when the primary tumor exceeds 2 cm in diameter. Effective screening measures that detect smaller tumors will considerably benefit asymptomatic LC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.